NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Trial Profile

NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Acronyms NEO-RIT
  • Sponsors Wissenschaftlicher Service Pharma
  • Most Recent Events

    • 15 Nov 2017 Results published in the International Journal of Radiation Oncology, Biology, Physics
    • 15 Nov 2017 Status changed from active, no longer recruiting to completed, according to results published in the International Journal of Radiation Oncology, Biology, Physics.
    • 12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top